2,5-DMA
2,5-dimethoxyamphetamine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2,5-DMA (2,5-dimethoxyamphetamine) is a synthetic stimulant of the phenethylamine class. It is the unsubstituted parent scaffold of the DOx psychedelic series — the base compound from which DOI, DOM, DOC, and DOB are derived. It weakly activates serotonin receptors,[1] producing physical stimulation without the perceptual shifts of classical psychedelics.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DOI, DOB, DOM +4 moreDOI, DOB, DOM, DOC, LSD, psilocybin, mescaline show less
First synthesized in 1939 at Burroughs Wellcome Research Laboratories for evaluation as a cardiovascular stimulant,[2] it was documented by Alexander Shulgin in PiHKAL in 1991, reporting purely physical effects with no perceptual alteration.[3] The WHO placed it under international Schedule I control in 1985;[4] no medical use has been found and no research is ongoing.
Subjective effects include cardiovascular stimulation, muscle tension, tremor, wakefulness, and heightened environmental interest. The experience is entirely physical — a somatic activation without visual, auditory, or cognitive alteration, closer to a moderate amphetamine dose than any classical psychedelic.[3] Nausea and sustained cardiovascular strain are the characteristic undesired effects.
2,5-DMA does not produce dependence,[5] and no lethal dose has been established in any species.[6] The primary risk is sympathomimetic overload — elevated heart rate, raised blood pressure, and elevated body temperature at high doses; MAOIs and other serotonergic drugs compound this sharply. Almost nothing has been formally studied; what is known comes from Shulgin's self-experiments and structural analogy to the DOx class.
History[edit]
Discovery
2,5-DMA was first synthesized in 1939 by Richard Baltzly and Johannes Buck at Burroughs Wellcome Research Laboratories, where it was evaluated for epinephrine-like cardiovascular activity.[2] Alexander Shulgin later documented it as PiHKAL entry #54 in 1991, reporting only physical effects — tremor and cardiovascular stimulation — with no perceptual change at any dose he tried.[3]
Scientific significance
2,5-DMA matters primarily as a structural parent. Adding a single group at the 4-position of its ring transforms it into full psychedelics — DOM, DOB, DOI, DOC — active at doses 20- to 80-fold lower.[7] It also had an unusual industrial role in Polaroid film manufacturing, creating anomalously large DEA production quotas for a Schedule I substance.[3][6]
Scheduling
The WHO reviewed 2,5-DMA in 1985 and placed it under Schedule I of the 1971 Convention on Psychotropic Substances.[4] It remains Schedule I internationally with no accepted medical use and no active research.
The name "DMA" stands for Di-Methoxy-amphetamine, with 2,5 denoting the positions of the methoxy groups on the ring. Among Shulgin's hundreds of documented compounds, 2,5-DMA is notable for what it lacks — despite being the structural ancestor of some of the most potent psychedelics ever synthesized, it produces no psychedelic effects at all. Shulgin described it as "totally a physical trip" and saw its significance as a chemical starting point, not a destination.[3]
Chemistry[edit]
Structural class
2,5-DMA belongs to the substituted amphetamine family of phenethylamines. It has an amphetamine backbone with methoxy groups at the 2- and 5-positions of the aromatic ring. This 2,5-dimethoxy arrangement defines the DOx pharmacophore — the chemical foundation shared by all DOx psychedelics. Its molecular formula is C₁₁H₁₇NO₂ (molecular weight 195.26 g/mol).
Adding a single lipophilic group at the 4-position of the ring — methyl, bromo, iodo, or chloro — transforms 2,5-DMA from a weak stimulant into a potent psychedelic, increasing serotonin receptor binding by orders of magnitude.[8]
This is why DOM, DOB, DOI, and DOC are far more powerful at far smaller doses. 2,5-DMA is also structurally related to mescaline, differing in the positions of its methoxy groups and the presence of an alpha-methyl group.
Pharmacology[edit]
Mechanism of action
2,5-DMA weakly activates serotonin receptors — roughly 300 times weaker than its close derivative DOI.[1][9] That weak binding directly explains why it produces physical stimulation rather than hallucinations. Full serotonin-activating psychedelics trigger glutamate release in the prefrontal cortex, disrupting normal brain signaling;[5] whether 2,5-DMA reaches sufficient receptor engagement to do the same is unknown.
Despite its amphetamine backbone, 2,5-DMA does not release dopamine, serotonin, or norepinephrine — the 2,5-dimethoxy substitution appears to abolish the monoamine-releasing activity characteristic of standard amphetamine.[10] A receptor called TAAR1 is a possible secondary target based on related compounds in the same structural series, but 2,5-DMA has not been specifically tested there.[10]
Pharmacokinetics
No pharmacokinetic data exist for 2,5-DMA in humans. Based on structural similarity to the DOx class, the body likely breaks it down via the liver enzyme CYP2D6 through O-demethylation.[11] Effects last approximately 6–8 hours by oral ingestion[3] — the only indirect constraint on how the body handles the compound.
Neuroscience[edit]
Where it acts
No neuroimaging or electrophysiology data exist for 2,5-DMA. By analogy to the DOx class, its primary target is serotonin receptors on neurons in the prefrontal cortex — where activation normally triggers downstream effects on brain signaling.[5] Whether 2,5-DMA's weak binding reaches that threshold, or whether its effects arise mainly through the peripheral nervous system, remains unknown.
Theoretical significance
Current models of psychedelic action predict that activating serotonin receptors above a certain level produces a breakdown in normal top-down brain organization — the disruption of predictive filtering that creates psychedelic perception and cognition. 2,5-DMA likely falls below that threshold. It functions as an implicit negative control: same chemical scaffold as the DOx psychedelics, insufficient receptor engagement, absent psychedelic phenomenology.
Several unresolved questions surround 2,5-DMA's neural pharmacology. Does it achieve any meaningful serotonin receptor occupancy in the brain at human-active doses, or are its effects entirely peripheral? Through what receptor or pathway does it produce sympathomimetic effects if it lacks monoamine transporter activity? Can it engage serotonin-dependent neuroplasticity pathways at achievable concentrations?
Subjective Effects[edit]
The experience of 2,5-DMA is pure physical activation. Heart rate rises, muscles tense, surroundings feel more engaging. There are no visual changes, no shift in cognition, nothing that resembles a psychedelic experience. Comfortable settings bring engaged alertness; uncomfortable ones bring restlessness.
Among the DOx series, 2,5-DMA sits at the baseline — the bare scaffold before any psychedelic potency is added. It resembles a moderate dose of amphetamine with a heavier peripheral load. Its relatives DOI and DOM produce full psychedelic experiences at doses 20- to 80-fold smaller.
Effect Grid
The core 2,5-DMA experience. Cardiovascular stimulation becomes prominent — increased heart rate and blood pressure are clearly noticeable. Tremor, muscle tension, and sustained wakefulness define the physical profile. Shulgin described 80 mg as 'totally a physical trip' with 'nothing of a sensory nature.'
Cognitive effects are limited to enhanced interest in surroundings and mild cognitive euphoria. The experience is 'largely pleasant' but lacks any visual, auditory, or perceptual alterations. No psychedelic phenomenology occurs despite 2,5-DMA's structural relationship to the DOx series.
Duration is 6–8 hours. Appetite suppression and insomnia are likely. Temperature dysregulation and excessive sweating may occur.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Auditory enhancement · Geometry · Sound sensitivity · Touch enhancement · Visual breathing · Visual processing acceleration · Tracers · Visual drifting · Visual haze / noise · Visual morphing
Touch enhancement · Visual breathing · Visual processing acceleration · Tracers · Visual drifting · Visual haze / noise · Visual morphing
Excessive sweating · Appetite suppression · Dry mouth · Body scan awareness · Muscle tension · Heart rate perception changes · Insomnia · Vasoconstriction · Spontaneous body sensations · Body high · Dehydration sensation · Physical fatigue · Respiratory stimulation · Restlessness · Bodily lightness · Breathing alteration · Bruxism · Headache · Laughter fits · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Motor control enhancement · Dizziness · Tactile euphoria · Trembling · Vibrations / buzzing · Vomiting
Body scan awareness · Muscle tension · Heart rate perception changes · Insomnia · Spontaneous body sensations · Body high · Dehydration sensation · Physical fatigue · Respiratory stimulation · Restlessness · Bodily lightness · Breathing alteration · Bruxism · Headache · Laughter fits · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Motor control enhancement · Dizziness · Tactile euphoria · Trembling · Vibrations / buzzing · Vomiting
Novelty enhancement · Aesthetic enhancement · Cognitive fatigue · Focus enhancement · Openness enhancement · Humor enhancement · Analysis enhancement · Creativity enhancement · Information processing enhancement · Thought connectivity · Pattern recognition enhancement · Cognitive flexibility · Conceptual thinking · Immersion enhancement · Introspection enhancement · Multiple thought streams · Language enhancement · Memory enhancement · Thought organization · Cognitive impairment · Confusion · Decision impairment · Increased nature relatedness · Thought disorganization · Thought loops
Focus enhancement · Openness enhancement · Humor enhancement · Analysis enhancement · Creativity enhancement · Information processing enhancement · Thought connectivity · Pattern recognition enhancement · Cognitive flexibility · Conceptual thinking · Immersion enhancement · Introspection enhancement · Multiple thought streams · Language enhancement · Memory enhancement · Thought organization · Cognitive impairment · Confusion · Increased nature relatedness · Thought disorganization · Thought loops
Emotional lability · Empathy enhancement · Irritability · Anhedonia · Catharsis · Simultaneous emotions · Dysphoria · Mania
Anhedonia · Catharsis · Simultaneous emotions · Dysphoria
Disinhibition · Social connection · Trust enhancement · Flow state · Ego inflation · Craving · Derealization · Depersonalization · Cognitive disconnection
Ego inflation · Craving · Derealization · Depersonalization · Cognitive disconnection
Timeline
Gradual physical activation becomes noticeable — mild cardiovascular awareness, slight increase in heart rate, emerging wakefulness. Effects are subtle and primarily somatic.
Sympathomimetic stimulation plateau — pronounced cardiovascular activation, tremor, muscle tension, sustained wakefulness, and enhanced environmental interest. No perceptual or visual changes. Shulgin described this phase as 'totally a physical trip.
Gradual diminution of stimulant effects — cardiovascular activation subsides, muscle tension eases, wakefulness persists at reduced intensity.
⚠ Do not drive or operate machinery until all residual stimulation and cardiovascular effects have fully resolved.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 8.5 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DOI · DOB · DOM
Toxicity
No lethal dose has been established for 2,5-DMA in any species, and no human overdose cases or fatalities have been published.[6] The toxic dose in humans is unknown.safety citation needed
Sympathomimetic risk
The primary concern is sympathomimetic overload: elevated heart rate, high blood pressure, elevated body temperature, and agitation.[3] These effects are documented at active doses and intensify with escalation.
Structurally related NBOMe compounds in severe poisoning cases produced rapid heart rate (90%), high blood pressure (70%), agitation (60%), and seizures.[12] 2,5-DMA is pharmacologically much weaker but shares the sympathomimetic component of this toxicity profile.inferred
Psychological risks
Shulgin's reports indicate minimal psychological effects at doses up to 80 mg — no perceptual disturbances or psychedelic-type distress.[3] No reports of anxiety, panic, psychosis, or perceptual flashbacks have been published.
At high doses, stimulant-associated effects — anxiety, restlessness, and paranoia — become possible. The WHO noted that higher doses produce amphetamine-like effects,[6] which may include these forms of stimulant agitation.
Tolerance and dependence
2,5-DMA does not produce dependence. Serotonin-activating psychedelics of this structural type do not generate the rewarding effects associated with addiction.[5] No physical dependence, withdrawal, or compulsive use has been reported.
Cross-tolerance with classical psychedelics is expected — repeated use of DOI causes rapid downregulation in the prefrontal cortex,[13] and cross-tolerance between phenethylamine psychedelics cannot be overcome by taking more.[14]
Drug interactions
The most dangerous combination is with MAOIs. MAOIs both amplify 2,5-DMA's serotonin activity and block the enzyme that breaks it down, raising both the intensity and duration of effects.inferred
Tramadol, SSRIs, and SNRIs all raise serotonergic load through different pathways. Combining any of them with 2,5-DMA risks serotonin syndrome — a life-threatening state of overheating, agitation, and seizures.safety citation neededinferred
Contraindications
The following are inferred from the sympathomimetic profileinferred:
Cardiovascular conditions: Pre-existing high blood pressure, heart rhythm disorders, coronary artery disease, and structural heart disease are contraindicated given documented cardiovascular stimulation.[3]
Seizure disorders: Sympathomimetic compounds may lower seizure threshold.inferred
Concurrent serotonergic medication: MAOIs, SSRIs, SNRIs, and tramadol are contraindicated due to serotonin toxicity risk.
Pregnancy and lactation: No reproductive safety data exist. Use is contraindicated.inferred
Harm Reduction[edit]
Forms & Identification
2,5-DMA is exceptionally rare on contemporary markets. Any material encountered is likely of research-chemical origin with no quality assurance. Given the high active dose (80–160 mg), it cannot fit on standard blotter paper — material sold as blotter is almost certainly mislabeled or a different substance.
Reagent testing can confirm the presence of a methoxylated amphetamine but cannot distinguish 2,5-DMA from its far more potent DOx derivatives. Quantitative analysis (GC-MS or comparable) is the only reliable identification method. Treat unverified material with extreme caution — confusion with DOx compounds active at 1–5 mg could produce a dangerous overdose if dosed at 2,5-DMA levels.
Guidelines
- Test all material with reagent kits AND quantitative analysis where possible — reagents alone cannot distinguish 2,5-DMA from far more potent DOx compounds
- Weigh doses with a milligram-precision scale; volumetric dosing is acceptable for solutions
- Start at the low end of the active range and wait at least 2 hours before considering redosing
- Monitor heart rate; if resting heart rate exceeds 120 bpm or chest discomfort develops, do not redose
- Ensure adequate hydration throughout the experience
- Avoid physical exertion that compounds cardiovascular strain
- Do not combine with other stimulants, serotonergic substances, or MAOIs
Set & Setting
The experience is predominantly physical — cardiovascular stimulation and wakefulness without perceptual change. A calm, comfortable environment reduces the likelihood of stimulant-associated anxiety. The 6–8 hour duration requires planning for a full day without obligations.
No psychological preparation for psychedelic-type experiences is necessary, as the compound does not produce them. A sitter is less critical than with psychedelics but remains advisable given the unknown toxicity profile and sympathomimetic cardiovascular load.
Aftercare & integration. The comedown resembles that of other stimulants — fatigue, mild low mood, and difficulty sleeping may follow. Prioritize sleep recovery in a dark, quiet environment, and avoid additional stimulants (including caffeine) for at least 12 hours after the experience.
Nutrition and hydration support recovery. Light meals during and after the experience help offset appetite suppression common to sympathomimetic compounds. No psychological integration is typically needed — the experience does not produce meaningful perceptual or cognitive alteration.
Recovery & Support
2,5-DMA does not produce physical dependence or withdrawal. Compulsive use patterns have not been documented. If stimulant use of any kind has become problematic, general stimulant recovery resources apply — including SMART Recovery, local addiction services, and peer support communities. Seek professional support if stimulant use is interfering with daily functioning, relationships, or health.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain or pressure
- Heart rate above 150 bpm or irregular heartbeat
- Severe headache with visual disturbance (possible blood pressure crisis)
- Body temperature high enough to feel through clothing
- Seizure or loss of consciousness
- Severe agitation unresponsive to reassurance
Immediate steps:
- Call emergency services if any of the above are present
- Move the person to a cool, quiet environment
- Remove excess clothing if body temperature is elevated
- Do not induce vomiting
- If unconscious but breathing, place in the recovery position
- Monitor breathing and pulse until help arrives
What to tell the dispatcher:
Name the substance (2,5-DMA or dimethoxyamphetamine), approximate amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
No specific reversal agent exists for sympathomimetic toxicity. Hospital treatment is supportive: cooling, blood pressure management, and sedation with benzodiazepines if needed.
Legal Status[edit]
2,5-DMA is internationally controlled under Schedule I of the 1971 United Nations Convention on Psychotropic Substances, following the WHO's 1985 recommendation.[4] Most jurisdictions classify it under broad amphetamine or phenethylamine scheduling provisions rather than substance-specific legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA Drug Code 7396; no accepted medical use[15] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under generic amphetamine/phenethylamine provision[15] |
| Canada | Schedule I (CDSA) | Controlled Drugs and Substances Act[15] |
| Australia | Controlled (narcotic) | Listed on Office of Drug Control register[16] |
| Germany | Controlled (NpSG) | Neue-psychoaktive-Stoffe-Gesetz since November 2016; possession not punishable but production and distribution are[16] |
| International | Schedule I (1971 Convention) | Recommended by WHO ECDD at 22nd meeting (1985)[4] |
Legal status changes frequently and varies by jurisdiction. The information above is not legal advice. Verify current law before taking any action.
The specific year 2,5-DMA was initially placed on Schedule I in the United States has not been confirmed; it may have been included under the broad amphetamine provisions of the Controlled Substances Act of 1970.citation needed
references
- [1] ^abHemanth P, Nistala P, Nguyen VT, Eltit JM, Glennon RA, Dukat M (2023) Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT2A and 5-HT2B serotonin receptors. — Frontiers in Pharmacology doi:10.3389/fphar.2023.1101290
- [2]
- [3]
- [4]
- [5] ^abcdHalberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens — Neuropharmacology doi:10.1016/j.neuropharm.2011.01.017
- [6]